

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI APPTec CO., LTD.\***  
**無錫藥明康德新藥開發股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2359)**

**VOLUNTARY ANNOUNCEMENT**

This announcement is made by WuXi AppTec Co., Ltd.\* (無錫藥明康德新藥開發股份有限公司) (the “**Company**” or “**WuXi AppTec**”) on a voluntary basis.

We have noticed that WuXi AppTec was named in a draft version of the Biosecure Act (the “**Draft Bill**”) introduced in the U.S. House of Representatives (the “**House**”) on January 25, 2024. There was also a similar draft bill recently introduced in the U.S. Senate. The Draft Bill has not been enacted into law and the legislative process requires the House and the U.S. Senate, after separate review by relevant committees in the House and the Senate, to vote on their respective versions of the bill and then agree on a final version. Therefore, the contents of the Draft Bill, including the reference to the Company, remain subject to further review and changes. We are working closely with our advisors to monitor the legislative process of the Draft Bill.

The Company notes that the Draft Bill contain certain alleged findings against WuXi AppTec. We believe such alleged findings are neither legitimate nor accurate. We are confident that the business development of WuXi AppTec will not pose a security risk to any country.

WuXi AppTec has been committed to abiding by laws and regulations in the countries in which we operate, including in both China and the U.S.. By adhering to our core value of “doing the right thing and doing it right”, we have served as a trusted partner in the global healthcare community, where for more than twenty years the Company has helped thousands of American and global customers with discovery, development, and manufacturing efforts to deliver innovative medicines that save and improve patients’ lives. We look forward to continuing to serve customers and help patients around the world.

By order of the Board  
**WuXi AppTec Co., Ltd.\***  
**Dr. Ge Li**  
*Chairman*

Hong Kong, January 26, 2024

*As of the date of this announcement, the board of directors of the Company comprises Dr. Ge Li, Dr. Minzhang Chen, Mr. Edward Hu, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Dai Feng as independent non-executive Directors.*

\* For identification purposes only